Advocacy groups sue EPA over approvals for two semiconductor chemicals tied to potential health risks

Environmental and community groups sued the Environmental Protection Agency on Friday over its approval of two chemicals for use in the semiconductor industry, alleging the Trump administration’s agency cleared the substances despite finding potential health risks, according to The Hill.

The lawsuit targets the EPA’s recent decision to approve the two unnamed chemicals used in semiconductor manufacturing. In its approval process, the EPA also identified potential risks to workers and the general public, the report says, setting up the core dispute as the plaintiffs argue the approvals were inconsistent with how the risks were evaluated.

The plaintiffs contend that the EPA’s approvals should be blocked and that the agency’s decision-making did not adequately account for the harms they say the chemicals could cause. The Hill reported that the suit challenges the agency’s action while pointing to the EPA’s own findings of potential exposure-related concerns.

EPA’s approvals, as described in the report, would allow broader use of the chemicals within the semiconductor supply chain. That means the practical stakes extend beyond lab testing and into day-to-day working conditions and community exposure considerations tied to how the chemicals are handled, regulated, and monitored across facilities producing advanced chips.

The lawsuit also highlights a familiar regulatory tension: agencies must balance industrial demand and innovation with health and safety safeguards, while courts evaluate whether the rulemaking or licensing process complied with administrative law requirements. In this case, the plaintiffs’ argument centers on the agency having recognized potential risks while still approving the chemicals for semiconductor use.

The Hill’s report frames the suit as part of ongoing litigation over federal environmental decision-making. The groups are seeking judicial intervention into EPA’s approval process, which could affect whether the approvals remain in place during the litigation or whether the agency must revisit aspects of its risk assessment.

The next steps will depend on how the case is scheduled and what relief the plaintiffs request, including whether the court takes up requests that could pause enforcement of the approvals while the merits are considered.